As end of New York opioid trial nears, AbbVie’s Allergan ponies up $200M to settle its part of the case

As end of New York opioid trial nears, AbbVie’s Allergan ponies up $200M to settle its part of the case
fkansteiner
Wed, 12/08/2021 – 14:22